Mayne Pharma Group Ltd (MYX) - Total Liabilities
Based on the latest financial reports, Mayne Pharma Group Ltd (MYX) has total liabilities worth AU$644.32 Million AUD (≈ $455.90 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset momentum of Mayne Pharma Group Ltd to track the company's year-over-year net asset growth rate.
Mayne Pharma Group Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how Mayne Pharma Group Ltd's total liabilities have evolved over time, based on quarterly financial data. See MYX FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Mayne Pharma Group Ltd Competitors by Total Liabilities
The table below lists competitors of Mayne Pharma Group Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Brazil Potash Corp.
NYSE:GRO
|
USA | $15.37 Million |
|
Daewon Sanup Co. Ltd
KQ:005710
|
Korea | ₩172.57 Billion |
|
Mineralbrunnen Überkingen-Teinach GmbH & Co. KGaA
F:MUT
|
Germany | €74.35 Million |
|
LG Household & Healthcare Ltd Pref
KO:051905
|
Korea | ₩1.30 Trillion |
|
Naturhouse Health SA
MC:NTH
|
Spain | €15.68 Million |
|
Kss Line
KO:044450
|
Korea | ₩1.49 Trillion |
|
Shinhan Seobu T&D REIT Co Ltd
KO:404990
|
Korea | ₩741.43 Billion |
|
Ecomate Holdings Bhd
KLSE:0239
|
Malaysia | RM65.68 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Mayne Pharma Group Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market value of Mayne Pharma Group Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.74 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mayne Pharma Group Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mayne Pharma Group Ltd (2006–2025)
The table below shows the annual total liabilities of Mayne Pharma Group Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$644.32 Million ≈ $455.90 Million |
-6.48% |
| 2024-06-30 | AU$688.99 Million ≈ $487.50 Million |
+12.40% |
| 2023-06-30 | AU$612.99 Million ≈ $433.73 Million |
-16.12% |
| 2022-06-30 | AU$730.81 Million ≈ $517.09 Million |
+5.67% |
| 2021-06-30 | AU$691.61 Million ≈ $489.35 Million |
-11.66% |
| 2020-06-30 | AU$782.87 Million ≈ $553.93 Million |
+25.81% |
| 2019-06-30 | AU$622.26 Million ≈ $440.29 Million |
+4.52% |
| 2018-06-30 | AU$595.35 Million ≈ $421.25 Million |
-1.19% |
| 2017-06-30 | AU$602.50 Million ≈ $426.30 Million |
-48.99% |
| 2016-06-30 | AU$1.18 Billion ≈ $835.75 Million |
+471.32% |
| 2015-06-30 | AU$206.74 Million ≈ $146.28 Million |
+94.04% |
| 2014-06-30 | AU$106.55 Million ≈ $75.39 Million |
-5.29% |
| 2013-06-30 | AU$112.50 Million ≈ $79.60 Million |
+382.16% |
| 2012-06-30 | AU$23.33 Million ≈ $16.51 Million |
-20.91% |
| 2011-06-30 | AU$29.50 Million ≈ $20.88 Million |
-35.30% |
| 2010-06-30 | AU$45.60 Million ≈ $32.26 Million |
+13654.27% |
| 2009-06-30 | AU$331.53K ≈ $234.58K |
+30.09% |
| 2008-06-30 | AU$254.85K ≈ $180.32K |
-74.42% |
| 2007-06-30 | AU$996.16K ≈ $704.84K |
+14130.80% |
| 2006-06-30 | AU$7.00K ≈ $4.95K |
-- |
About Mayne Pharma Group Ltd
Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract developmen… Read more